Focused On-demand Library for C-type lectin domain family 4 member C

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q8WTT0

UPID:

CLC4C_HUMAN

Alternative names:

Blood dendritic cell antigen 2; C-type lectin superfamily member 7; Dendritic lectin

Alternative UPACC:

Q8WTT0; D3DUU3; Q3T1C3; Q6UXS8; Q8WXX8

Background:

C-type lectin domain family 4 member C, also known as Blood dendritic cell antigen 2, plays a crucial role in the immune system. It functions as a lectin-type cell surface receptor, involved in antigen capturing by dendritic cells. This protein specifically recognizes non-sialylated galactose-terminated biantennary glycans and binds to serum IgG, facilitating efficient targeting of ligand into antigen-processing compartments for T-cell presentation. It may also inhibit IFN-alpha/beta expression in plasmacytoid dendritic cells and act as a signaling receptor.

Therapeutic significance:

Understanding the role of C-type lectin domain family 4 member C could open doors to potential therapeutic strategies.